Page 1 of 2 09/454737 Search results

Refine Search

Search Results -

Terms	Documents
L10 and thrombolytic	2

Database:

US Pre-Grant Publication Full-Text Database
US Patents Full-Text Database
US OCR Full-Text Database
EPO Abstracts Database
JPO Abstracts Database

Derwent World Patents Index IBM Technical Disclosure Bulletins

Search:

L11			2	Refine Search
(3/7/20/2/20/2/20/2/20/2/20/2/20/2/20/2/2	Recall Text	Clear		Interrupt

Search History

DATE: Friday, January 09, 2004 Printable Copy Create Case

Set Name side by side	Query	Hit Count	Set Name result set
DB=P	PGPB, USPT, USOC, EPAB, JPAB, DWPI, TDBD; PLUR=YES; OP=OR		
L11 '	L10 and thrombolytic	2	<u>L11</u>
L10	L9 and adenovir\$ near10 (replication near defective or non near replicativ\$)	. 77	<u>L10</u> .
<u>L9</u>	adenovir\$ and vector\$ and (RSV or rous) near5 promoter\$ and "E1" and muscle\$ and dystrophin	175	<u>L9</u>
<u>L8</u>	adenovir\$ and vector\$ and (RSV or rous) and "E1" and muscle\$ and dystrophin	220	<u>L8</u>
<u>L7</u>	adenovir\$ near20 (RSV or rous)	2251	<u>L7</u>
	L5 and dystrophin	5	<u>L6</u>
L5	L4 and (non near replicative or replication near defective)	29	<u>L5</u>
$ \begin{array}{c} \underline{L6} \\ \underline{L5} \\ \underline{L4} \\ \underline{L3} \end{array} $	L3 and "E1"	52	<u>L4</u>
L3	L1 and muscle\$	127	<u>L3</u>
L2	adenovir\$ near5 vector\$ near20 (RSV or rous) near5 promoter\$	44	<u>L2</u>

L1 adenovir\$ near5 vector\$ near20 (RSV or rous)

182 L1

END OF SEARCH HISTORY

Generate Collection

Print


Search Results - Record(s) 1 through 77 of 77 returned.


1. 20040003424. 04 Mar 03. 01 Jan 04. Transgenic cardiomyocytes with controlled proliferation and differentiation. Olson, Eric, et al. 800/18; 435/354 800/21 A01K067/027 C12N005/06.
2. 20030219410. 31 Jan 03. 27 Nov 03. Adenoviral vectors for modulating the cellular activities associated to PODs. Calatrava, Manuel Rosa. 424/93.2; 435/456 A61K048/00 C12N015/861.
3. 20030212022. 12 Dec 02. 13 Nov 03. Compositions and methods for gene therapy. Vogel, Jean-Marie, et al. 514/44; 424/493 435/455 A61K048/00 A61K009/16 A61K009/50 C12N015/85.
4. 20030211513. 09 Dec 02. 13 Nov 03. Intracellular signaling proteins. Yue, Henry, et al. 435/6; 435/320.1 435/325 435/69.1 530/350 530/388.1 536/23.5 C12Q001/68 C07H021/04 C07K014/47 C12P021/02 C12N005/06 C07K016/18.
5. 20030211165. 12 Dec 02. 13 Nov 03. Microspheres for active embolization. Vogel, Jean-Marie, et al. 424/493; 424/497 514/54 A61K009/14 A61K009/16 A61K009/50 A61K031/715.
6. 20030186337. 10 Dec 02. 02 Oct 03. Novel death associated proteins, and THAP1 and PAR4 pathways in apoptosis control. Girard, Jean-Philippe, et al. 435/7.23; 435/226 435/320.1 435/325 435/69.1 536/23.2 G01N033/574 C07H021/04 C12N009/64 C12P021/02 C12N005/06.
7. 20030175243. 01 Apr 03. 18 Sep 03. Modified adenoviral fiber and target adenoviruses. Legrand, Valerie, et al. 424/93.2; 435/235.1 435/325 435/456 530/350 A61K048/00 C12N007/00 C12N015/861 C12N005/00.
8. 20030165835. 14 May 01. 04 Sep 03. Cell stress regulated human MHC class I gene. Spies, Thomas, et al. 435/6; 424/155.1 424/93.21 435/366 435/7.23 800/18 800/8 C12Q001/68 G01N033/574 A01K067/027 A61K048/00 A61K039/395 C12N005/08.
9. 20030157688. 14 Jan 00. 21 Aug 03. Adenovirus vectors, packaging cell lines, compositions, and methods for preparation and use. Von Seggern, Daniel J., et al. 435/235.1; 424/93.2 435/325 435/456 536/23.2 A61K048/00 C07H021/04 C12N007/00 C12N015/861.
10. 20030157064. 08 Nov 02. 21 Aug 03. Chimeric promoters for controlling expression in muscle cells. Neuville, Pascal, et al. 424/93.2; 435/320.1 435/456 A61K048/00 C12N015/86.
11. 20030144176. 30 May 02. 31 Jul 03. Methods and compositions relating to MEK5 and cardiac hypertrophy and dilated cardiomyopathy. Olson, Eric N., et al. 514/1; 514/651 A61K031/00 A61K031/135 A61K031/137.
☐ 12. 20030143702. 31 Oct 02. 31 Jul 03. Vesicular monoamine transporter gene therapy in parkinson's disease. Kang, Un Jung. 435/128; 435/325 435/455 435/456 C12P013/00 C12N015/861 C12N015/867 C12N005/06.
13. 20030143228. 29 Oct 02. 31 Jul 03. Human telomerase reverse transcriptase as a class-II restricted tumor-associated antigen. Chen, Si-Yi, et al. 424/144.1; 435/320.1 435/334 435/69.1

530/388.22 536/23.53 A61K039/395 C07H021/04 C07K016/28 C12P021/02 C12N005/06 C07K014/74. 14. 20030143209. 22 Feb 01. 31 Jul 03. Targeted adenovirus vectors for delivery of heterologous genes. Vigne, Emmanuelle, et al. 424/93.21; 435/235.1 A61K048/00 C12N007/00 C12N007/01. 15. 20030139324. 19 Nov 02. 24 Jul 03. Tumor suppressor designated TS10q23.3. Steck, Peter, et al. 514/2; 435/184 435/320.1 435/325 435/6 435/7.23 536/23.2 A61K038/17 C12Q001/68 G01N033/574 C12N009/99 C07H021/04 C12P021/02 C12N005/06. 16. 20030138412. 27 Jun 02. 24 Jul 03. Inhibition of tumor growth and metastasis by N5 gene. Goodrich, David W., et al. 424/93.21; 435/7.23 514/44 A61K048/00 G01N033/574. 17. 20030119191. 20 Sep 02. 26 Jun 03. Compositions and methods for helper-free production of recombinant adeno-associated viruses. Gao, Guangping, et al. 435/456; 435/235.1 C12N015/861 C12N007/00. 18. 20030113301. 21 Mar 02. 19 Jun 03. Muscle cells and their use in cardiac repair. Edge, Albert, et al. 424/93.21; 424/93.7 A61K048/00. 19. 20030108521. 30 May 02. 12 Jun 03. Adenovirus protein IX, its domains involved in capsid assembly, transcriptional activity and nuclear reorganization. Calatrava, Manuel Rosa. 424/93.2; 424/186.1 435/235.1 435/320.1 435/325 435/456 435/69.3 530/350 536/23.72 A61K048/00 A61K039/12 C07H021/04 C12P021/02 C12N005/06 C07K014/075 C12N007/00 C12N015/861. 20. 20030096782. 11 Sep 02. 22 May 03. Expression profiling in the intact human heart. Bristow, Michael R., et al. 514/44; 435/6 A61K048/00 C12Q001/68. 21. 20030092161. 19 Sep 02. 15 May 03. Compositions and methods for production of recombinant viruses, and uses therefor. Gao, Guangping, et al. 435/235.1; 435/239 435/456 C12N007/00 C12N007/02 C12N015/86. 22. 20030087247. 12 Feb 02. 08 May 03. Diagnosis and treatment of inflammation and hyperactive immune conditions. Kumamoto, Tadashi, et al. 435/6; 435/4 C12Q001/68 C12Q001/00. 23. 20030078376. 07 Nov 01. 24 Apr 03. Methods and compositions relating to muscle specific sarcomeric calcineurin-binding proteins (calsarcins). Olson, Eric, et al. 530/350; C07K001/00 C07K014/00 C07K017/00. 24. 20030077810. 15 Feb 02. 24 Apr 03. CHAMP - a novel cardiac helicase-like factor. Olson, Eric, et al. 435/226; 435/320.1 435/325 435/6 435/69.1 536/23.2 C12Q001/68 C07H021/04 C12N009/64 C12P021/02 C12N005/06. 25. 20030026783. 03 Aug 01. 06 Feb 03. Method of modulating neutralizing antibodies formation in mammals, and uses thereof in gene therapy, animal transgenesis and in functional inactivation of an endogenous proteins. Abina, Amine. 424/93.2; 424/131.1 424/450 514/44 A61K048/00 A61K039/395 A61K009/127. 26. 20020164735. 21 Dec 01. 07 Nov 02. Methods and compositions relating to a cardiac-specific nuclear regulatory factor. Olson, Eric N., et al. 435/183; 435/320.1 435/325 435/69.1 536/23.2

C12N009/00 C07H021/04 C12P021/02 C12N005/06.

27. 20020150953. 13 Feb 01. 17 Oct 02. Methods and compositions relating to muscle selective calcineurin interacting protein (MCIP). Williams, R. Sanders, et al. 435/7.23; 424/9.2 435/7.92 G01N033/574 G01N033/53 G01N033/537 G01N033/543 A61K049/00. 28. 20020127690. 18 Jul 01. 12 Sep 02. Methods and compositions for stabilizing microtubules and intermediate filaments in striated muscle cells. Olson, Eric N., et al. 435/226; 435/320.1 435/325 435/456 435/69.1 536/23.2 C12N009/64 C07H021/04 C12P021/02 C12N005/06. 29. 20020106746. 04 Oct 01. 08 Aug 02. Anti-inflammatory vectors. Rooke, Ronald. 435/91.33; 424/199.1 424/204.1 424/233.1 424/93.21 435/235.1 435/320.1 435/456 435/91.41 530/388.7 536/23.72 A61K048/00 C12N007/00 C12N015/861 C07H021/04 C12P019/34 C12N015/64 C12N015/66 A01N063/00 A61K039/12 A61K039/23 A61K039/235 C12N007/01 C12N015/00 C12N015/09 C12N015/63 C12N015/70 C12N015/74 C07K016/00 C12P021/08 C12N015/86. 30. 20020088014. 10 Oct 01. 04 Jul 02. Minimal adenovirus mediated recombinant vaccine. Fang, Xiangming, et al. 800/8; 435/235.1 435/320.1 435/456 A01K067/00 C12N015/867 C12N015/861 C12N007/00 C12N007/01. 31. 20020086427. 22 Mar 01. 04 Jul 02. Inducible eukaryotic expression system that regulates protein translation. Leiden, Jeffrey M., et al. 435/455; A61K031/70 C12N015/63. 32. 20020072120. 03 Aug 01. 13 Jun 02. Helper viruses for the preparation of recombinant viral vectors. Lusky, Monika, et al. 435/457; 435/235.1 435/325 435/69.1 C12N015/861 C12N007/00 C12P021/02 C12N005/06. 33. 20020042139. 31 May 01. 11 Apr 02. Methods and compositions for efficient gene transfer using transcomplementary vectors. Higginbotham, James N., et al. 435/457; C12N015/861. 34. 20020019051. 31 May 01. 14 Feb 02. Chimeric adenoviral vectors. Lusky, Monika, et al. 435/457; 435/235.1 C12N015/861 C12N007/01. 35. 20020019050. 05 Apr 01. 14 Feb 02. Compositions and methods for helper-free production of recombinant adeno-associated viruses. Gao, Guangping, et al. 435/456; 435/235.1 C12N015/861 C12N007/01. 36. 20020006395. 15 Apr 97. 17 Jan 02. DEFECTIVE ADENOVIRUSES INCLUDING A THERAPEUTIC GENE AND AN IMMUNOPROTECTIVE GENE. PERRICAUDET, MICHEL, et al. 424/93.21; 435/235.1 A61K048/00 C12N007/00. 37. 20010036929. 26 Apr 01. 01 Nov 01. Xrcc3 is required for assembly of Rad51-complexes in vivo. Weichselbaum, Ralph R., et al. 514/44; 424/649 514/34 A61K048/00 A61K033/24. 38. 20010011078. 22 Dec 00. 02 Aug 01. DNA fragmentation factor involved in apoptosis. Wang, Xiaodong, et al. 514/44; 424/93.2 424/94.6 435/196 435/320.1 435/6 530/388.26 536/23.2 A61K048/00 C07H021/04 C07K016/40 A61K038/46 C12N009/16 A61K031/713. 39. 6673604. 24 Jul 00; 06 Jan 04. Muscle cells and their use in cardiac repair. Edge; Albert. 435/347; 435/325 435/371. C12N005/06 C12N005/08. 40. 6669942. 15 Apr 97; 30 Dec 03. Defective adenoviruses including a therapeutic gene and an





Generate Collection Print
77. 5891690. 26 Apr 96; 06 Apr 99. Adenovirus E1-complementing cell lines. Massie; Bernard. 435/456; 435/235.1 435/371. C12N005/10 C12N015/86 C12N015/87.
76. 5994132. 23 Oct 96; 30 Nov 99. Adenovirus vectors. Chamberlain; Jeffrey S., et al. 435/369; 435/320.1. C12N005/08 C12N005/10 C12N015/86.
75. 6001557. 25 Aug 97; 14 Dec 99. Adenovirus and methods of use thereof. Wilson; James M., et al. 435/5; 435/239 435/320.1 435/325 435/366 435/367 435/368 435/369 435/6 435/91.4 530/300. C12Q001/70 C12N015/86 C12N015/64.
74. 6022735. 25 May 95; 08 Feb 00. Composition for introducing nucleic acid complexes into higher eucaryotic cells. Curiel; David T., et al. 435/320.1; 435/455 435/456 514/12 514/2 514/44 530/300 530/325 530/350 530/387.5 530/388.21 530/388.22 536/23.1. C12N015/63 C12N015/00 C12Q001/70 C07H021/04.
☐ 73. 6063622. 05 Feb 99; 16 May 00. Adenovirus vectors. Chamberlain; Jeffrey S., et al. 435/369; 435/235.1 435/320.1 435/325. C12N005/10 C12N007/01 C12N015/86.
72. 6066478. 09 Mar 98; 23 May 00. Helper viruses for preparing recombinant viral vectors. Lusky; Monika, et al. 435/91.41; 435/320.1 435/325 435/366 435/369 435/455 435/456 435/457 435/91.4 435/91.42 536/23.2 536/23.4 536/23.5 536/23.7. C12N015/64 C12N015/861 C12N005/10 C07H021/04.
71. 6083750. 05 Feb 99; 04 Jul 00. Adenovirus vectors. Chamberlain; Jeffrey S., et al. 435/369; 435/320.1 435/325. C12N005/10 C12N015/86.
☐ 70. 6110735. 01 Aug 96; 29 Aug 00. Method for the preparation of a viral vector by intermolecular homologous recombination. Chartier; Cecile, et al. 435/320.1; 424/233.1 435/235.1 435/252.1 435/252.3 435/252.8 435/91.4 435/91.41 514/44 530/350. A61K039/235 C07H021/04 C07K014/075 C12N001/21.
☐ 69. 6110744. 12 Nov 97; 29 Aug 00. Diminishing viral gene expression by promoter replacement. Fang; Bingliang, et al. 435/456; 435/320.1 536/23.1 536/23.5 536/23.7 536/23.72 536/24.1. C12N015/64 C12N015/34 C12N015/12.
☐ 68. 6156497. 13 Apr 98; 05 Dec 00. Recombinase-mediated generation of adenoviral vectors. Kaleko; Michael. 435/5; 435/320.1 435/462 435/91.4 536/23.1. C12Q001/70 C12P019/34 C12N015/87 C12N015/63 C07H021/04.
67. 6165737. 16 Apr 98; 26 Dec 00. DNA fragmentation factor involved in apoptosis. Wang; Xiaodong, et al. 435/7.6; 435/23 435/252.3 435/252.33 435/320.1 435/7.91 536/23.2. C12Q001/00 C12Q001/37 C12N009/64 C12N015/70 C12N015/74.
Thigpen; Anice, et al. 435/325; 424/196.11 424/204.1 424/93.21 424/93.3 424/94.4 435/14 435/176 435/183 435/234 435/235.1 435/252.3 435/254.11 435/3 435/30 435/317.1 435/320.1 435/34 435/366 435/372.3 435/375 435/440 435/455 435/465 435/69.1 435/69.4 435/69.7 514/10 514 /14 514/169 514/31 514/564 514/806 514/9. C12N015/00.

Terms	Documents
L9 and adenovir\$ near10 (replication near defective or non near replicativ\$)	77

Prev Page Next Page Go to Doc#



Day: Friday Date: 1/9/2004 Time: 10:47:32

Inventor Name Search

Enter the **first few letters** of the Inventor's Last Name. Additionally, enter the **first few letters** of the Inventor's First name.

Last Name	First Name	
perricaudet	michel	Search

To go back use Back button on your browser toolbar.

Back to PALM | ASSIGNMENT | OASIS | Home page



PALM INTRANET

Search

Day: Friday Date: 1/9/2004 Time: 10:47:32

Inventor Name Search

Enter the **first few letters** of the Inventor's Last Name. Additionally, enter the **first few letters** of the Inventor's First name.

Last Name	First Name
briand	pascale

To go back use Back button on your browser toolbar.

Back to PALM | ASSIGNMENT | OASIS | Home page